The 3rd International Online Conference on Toxins







Zuzanna Tomkielska ^{1,2}, Jorge Frias ¹, Ana Casas ², Nelson Simões ¹, and Duarte Toubarro* ¹

- ¹ Center of Biotechnology of Azores (CBA), University of Azores, 9500-321 Ponta Delgada, Portugal
 - ² Mesosystem Investigação & Investimentos by Spinpark, Barco, 4805-017 Guimarães, Portugal
 - * Correspondence: duarte.nt.tiago@uac.pt

INTRODUCTION & AIM

Animal venoms are increasingly recognized as rich sources of bioactive molecules with therapeutic potential, particularly peptides targeting voltage-gated ion channels, which play critical roles in physiological processes and are implicated in a wide range of diseases. Among these, ShK-like peptides, originally discovered in sea anemone venom, have emerged as potent and selective modulators of Kv channels, highlighting the potential of venom-derived molecules in drug development. In this study, we report the discovery of 30 ShK-like domains in the venom of Physalia physalis, identified through proteomic analysis and predicted to selectively modulate specific Kv channel subtypes. The aim of this work was to identify, characterize, and functionally validate one of these novel peptides, with a particular focus on their inhibitory activity against the Kv1.3 channel, a key therapeutic target involved in autoimmune disorders, pain, and neurological diseases.

METHOD

Proteomic analysis

Venom was analyzed by LC-MS/MS (CIEX TripleTOF 6600), and spectra were searched against NCBI (Cnidaria-restricted) and a custom transcriptome-derived database (NCBI Accession SUB13325220).

Structure prediction and docking

3D structures of the ShK-like peptides were predicted using AlphaFold2 and subsequently docked against a panel of human Kv1 channels with ZDOCK.

Selection of the peptide based on the docking results

ShK26_D5

Vector construction

One of the most promising ShK variant was expressed in E. coli using the pET-40 vector, targeted to the periplasmic space in fusion with DsbC to promote correct disulfide bond formation, and carrying a His-tag.

Heterologous expression

Protein production was carried out in E. coli C41 using AI medium ZYM-5052 (2h at 37°C followed by 6h at 30°C, yield approx. 1 g/L pellet per cell culture) and purified by FPLC using a HisTrap and Desalting column.

Target validation


Functional characterization was performed using automated whole-cell patch-clamp electrophysiology (SynchroPatch 384i) on fibroblasts heterologously transfected with Kv1.3, and Quinidine as the reference compound. A peak pulse protocol, from a holding potential of -80 mV to +60 mV over 300 ms, was applied every 20 seconds to monitor the outward current.


Radioligand competition assay

Evaluation of the affinity of the compound (10 μ M) for the Kv channel in the human cerebral cortex was determined in a competition assay with radiolabeled α -[125I]dendrotoxin (20nM and 50nM for non-specific binding).

RESULTS & DISCUSSION

1. Proteomic analysis of *P. physalis* venom revealed the presence of multiple ShK-like domains.






2. Al-based platform predicts the 3D


structure of the peptides with highly

conserved Cys residues.




Multiple ShK-like peptides tandemly arranged in a single coding sequence.

3. Docking against the panel of human Kv1 channels reveals peptides with Kv1.3 preference.




Peptide ShK26_D5 was selected for recombinant production based on its low binding energy and direct binding to the pore of the Kv1.3. Green structure represents the pore of the Kv1.3 channel while red represents ShK26 D5 peptide.

5. Whole-cell patch-clamp confirmed activity of ShK26_D5 at nanomolar concentrations.




Patch-clamp recordings demonstrate that **20 nM** of the peptide effectively inhibits Kv1.3 currents, confirming its strong blocking activity. Open state (grey), inhibition with peptide (blue) and fully blocked channel (black).




- **Highly conserved** 2-3 **disulfide bridges** that stabilize the structure
- 33-47 residues

4. Expression and purification of the ShK26_D5 peptide.



ShK26 D5 was expressed in a soluble form. Upper chromatogram: His-tag purification; lower chromatogram: desalting.

6. Competition assay on a cerebral cortex tissue with radiolabeled α -[125l]dendrotoxin



The recombinant ShK26_D5 peptide showed **low** competition (4%) against Kv1.1, Kv1.2, and Kv1.6, even at 200x higher concentrations than the reference compound, which minimizes the risk of neurological side effects.

CONCLUSION

- Physalia physalis venom contains 30 ShK-like peptides with potential as selective Kv channel modulators.
- The recombinant ShK26 D5 peptide showed **blocking activity on the Kv1.3** channel, with minimal competition against Kv1.1, Kv1.2, and Kv1.6, reducing the likelihood of off-target interactions associated with severe side effects, placing it as a promising candidate for therapeutic applications in Kv1.3-mediated disorders.

FUTURE WORK / REFERENCES

Future studies should address functional validation in neuronal and immune cells and in a vertebrate model to evaluate therapeutic potential and safety.

ACKNOWLEDGEMENT

This research was funded by Project EEA Grants - number: MOD.PN.FRM.59.PT.V03 - Physalia Physalis - Innovative and unexploited source of high added-value cosmetic products.







